| Literature DB >> 25190691 |
Peter R Carroll1, J Kellogg Parsons1, Gerald Andriole1, Robert R Bahnson1, Daniel A Barocas1, William J Catalona1, Douglas M Dahl1, John W Davis1, Jonathan I Epstein1, Ruth B Etzioni1, Veda N Giri1, George P Hemstreet1, Mark H Kawachi1, Paul H Lange1, Kevin R Loughlin1, William Lowrance1, Paul Maroni1, James Mohler1, Todd M Morgan1, Robert B Nadler1, Michael Poch1, Chuck Scales1, Terrence M Shanefelt1, Andrew J Vickers1, Robert Wake1, Dorothy A Shead1, Maria Ho1.
Abstract
The NCCN Guidelines for Prostate Cancer Early Detection provide recommendations for men choosing to participate in an early detection program for prostate cancer. These NCCN Guidelines Insights highlight notable recent updates. Overall, the 2014 update represents a more streamlined and concise set of recommendations. The panel stratified the age ranges at which initiating testing for prostate cancer should be considered. Indications for biopsy include both a cutpoint and the use of multiple risk variables in combination. In addition to other biomarkers of specificity, the Prostate Health Index has been included to aid biopsy decisions in certain men, given recent FDA approvals.Entities:
Mesh：
Year: 2014 PMID： 25190691 DOI： 10.6004/jnccn.2014.0120
Source DB: PubMed Journal: J Natl Compr Canc Netw ISSN： 1540-1405 Impact factor: 11.908